Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia
© 2021 British Society for Haematology and John Wiley & Sons Ltd..
Patients with asymptomatic/smouldering Waldenström macroglobulinaemia (SWM) have a variable risk of progression to active WM. Our study evaluated 143 patients with SWM consecutively seen between January 1996 and December 2013. With a median [95% confidence interval (CI)] follow-up of 9·5 [8·1-11·5] years, the cumulative rate of progression was 11% at 1 year, 38% at 3 years and 55% at 5 years. On multivariate analysis, haemoglobin (Hb) ≤123 g/l [risk ratio (RR) 2·08; P = 0·009] and β2 -microglobulin (β2 M) ≥2·7 µg/ml (RR 2·0; P = 0·01) were independent predictors of a shorter time-to-progression (TTP) to active WM. Patients with myeloid differentiation factor 88 wild type (MYD88WT ) genotype (n = 11) demonstrated a trend toward shorter TTP [median (95% CI) 1·7 (0·7-8·7) vs. 4·7 (2·4-7·7) years for the MYD88L265P cohort, n = 42; P = 0·11]. The presence of C-X-C chemokine receptor type 4 (CXCR4) mutation (n = 29) did not impact the TTP (median: 3 years for CXCR4WT vs. 5·6 years for CXCR4MUT , P = 0·34). The overall survival (OS) for patients with SWM (median: 18·1 years) was comparable to an age-, sex- and calendar year-matched USA population (median: 20·3 years, P = 0·502). In conclusion, Hb and β2 M at diagnosis represent independent predictors of progression to active WM. Comparable survival of SWM and a matched USA population argues against pre-emptive intervention in this patient population.
| Errataetall: |
CommentIn: Br J Haematol. 2021 Oct;195(2):155-157. - PMID 34472092 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:195 |
|---|---|
| Enthalten in: |
British journal of haematology - 195(2021), 2 vom: 20. Okt., Seite 210-216 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zanwar, Saurabh [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.12.2021 Date Revised 16.12.2021 published: Print-Electronic CommentIn: Br J Haematol. 2021 Oct;195(2):155-157. - PMID 34472092 Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.17691 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328847607 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328847607 | ||
| 003 | DE-627 | ||
| 005 | 20231225203826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.17691 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1096.xml |
| 035 | |a (DE-627)NLM328847607 | ||
| 035 | |a (NLM)34340248 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zanwar, Saurabh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2021 | ||
| 500 | |a Date Revised 16.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Br J Haematol. 2021 Oct;195(2):155-157. - PMID 34472092 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Patients with asymptomatic/smouldering Waldenström macroglobulinaemia (SWM) have a variable risk of progression to active WM. Our study evaluated 143 patients with SWM consecutively seen between January 1996 and December 2013. With a median [95% confidence interval (CI)] follow-up of 9·5 [8·1-11·5] years, the cumulative rate of progression was 11% at 1 year, 38% at 3 years and 55% at 5 years. On multivariate analysis, haemoglobin (Hb) ≤123 g/l [risk ratio (RR) 2·08; P = 0·009] and β2 -microglobulin (β2 M) ≥2·7 µg/ml (RR 2·0; P = 0·01) were independent predictors of a shorter time-to-progression (TTP) to active WM. Patients with myeloid differentiation factor 88 wild type (MYD88WT ) genotype (n = 11) demonstrated a trend toward shorter TTP [median (95% CI) 1·7 (0·7-8·7) vs. 4·7 (2·4-7·7) years for the MYD88L265P cohort, n = 42; P = 0·11]. The presence of C-X-C chemokine receptor type 4 (CXCR4) mutation (n = 29) did not impact the TTP (median: 3 years for CXCR4WT vs. 5·6 years for CXCR4MUT , P = 0·34). The overall survival (OS) for patients with SWM (median: 18·1 years) was comparable to an age-, sex- and calendar year-matched USA population (median: 20·3 years, P = 0·502). In conclusion, Hb and β2 M at diagnosis represent independent predictors of progression to active WM. Comparable survival of SWM and a matched USA population argues against pre-emptive intervention in this patient population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CXCR4 | |
| 650 | 4 | |a IgM monoclonal gammopathy | |
| 650 | 4 | |a MYD88 | |
| 650 | 4 | |a asymptomatic lymphoplasmacytic lymphoma | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a CXCR4 protein, human |2 NLM | |
| 650 | 7 | |a Hemoglobins |2 NLM | |
| 650 | 7 | |a Myeloid Differentiation Factor 88 |2 NLM | |
| 650 | 7 | |a Receptors, CXCR4 |2 NLM | |
| 650 | 7 | |a beta 2-Microglobulin |2 NLM | |
| 700 | 1 | |a Abeykoon, Jithma P |e verfasserin |4 aut | |
| 700 | 1 | |a Ansell, Stephen M |e verfasserin |4 aut | |
| 700 | 1 | |a Gertz, Morie A |e verfasserin |4 aut | |
| 700 | 1 | |a Colby, Colin |e verfasserin |4 aut | |
| 700 | 1 | |a Larson, Dirk |e verfasserin |4 aut | |
| 700 | 1 | |a Paludo, Jonas |e verfasserin |4 aut | |
| 700 | 1 | |a He, Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Warsame, Rahma |e verfasserin |4 aut | |
| 700 | 1 | |a Greipp, Patricia T |e verfasserin |4 aut | |
| 700 | 1 | |a King, Rebecca L |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, Carrie A |e verfasserin |4 aut | |
| 700 | 1 | |a Witzig, Thomas E |e verfasserin |4 aut | |
| 700 | 1 | |a Lacy, Martha Q |e verfasserin |4 aut | |
| 700 | 1 | |a Gonsalves, Wilson |e verfasserin |4 aut | |
| 700 | 1 | |a Nowakowski, Grzegorz S |e verfasserin |4 aut | |
| 700 | 1 | |a Dingli, David |e verfasserin |4 aut | |
| 700 | 1 | |a Go, Ronald S |e verfasserin |4 aut | |
| 700 | 1 | |a Habermann, Thomas M |e verfasserin |4 aut | |
| 700 | 1 | |a Vincent Rajkumar, S |e verfasserin |4 aut | |
| 700 | 1 | |a Kyle, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Shaji |e verfasserin |4 aut | |
| 700 | 1 | |a Kapoor, Prashant |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 195(2021), 2 vom: 20. Okt., Seite 210-216 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:195 |g year:2021 |g number:2 |g day:20 |g month:10 |g pages:210-216 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.17691 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 195 |j 2021 |e 2 |b 20 |c 10 |h 210-216 | ||